Results 171 to 180 of about 8,702 (224)

Therapeutic Use of γ-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy. [PDF]

CNS Drugs
Roth T.
europepmc   +1 more source

Parkinson's disease, sleepiness and hypocretin/orexin [PDF]

, 2017
Bassetti, Claudio L., Baumann, Christian R., Scammell, Thomas E.   +2 more
core  

Pharmacological inhibition of histamine N-methyltransferase extends wakefulness and suppresses cataplexy in a mouse model of narcolepsy. [PDF]

Sleep
Naganuma F, Girgin B, Agu ABS, Hirano K, Nakamura T, Yanai K, Vetrivelan R, Mochizuki T, Yanagisawa M, Yoshikawa T.   +9 more
europepmc   +1 more source

Guillain-Barré syndrome with unilateral oculomotor nerve palsy and anti-GM3 IgG antibodies. [PDF]

Sci Prog
Xiao M, Huang X.
europepmc   +1 more source

Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection. [PDF]

Ann Clin Transl Neurol
Wang X, Zhang X, Yuan N, Liu Y.
europepmc   +1 more source

Xywav: A Treatment Option for Idiopathic Hypersomnia in Down Syndrome. [PDF]

Cureus
Sanchez S, Allen J.
europepmc   +1 more source

[Narcolepsy-cataplexy].

Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985), 1989
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Narcolepsy with cataplexy

Lancet, The, 2007
Narcolepsy with cataplexy is a disabling sleep disorder affecting 0.02% of adults worldwide. It is characterised by severe, irresistible daytime sleepiness and sudden loss of muscle tone (cataplexy), and can be associated with sleep-onset or sleep-offset paralysis and hallucinations, frequent movement and awakening during sleep, and weight gain.
yves Dauvilliers, Isabelle Arnulf
exaly   +3 more sources